Serum α-1-acid glycoprotein as an index of dissemination in breast cancer

Roberts, John G.; Keyser, J. W.; Baum, Michael

doi:10.1002/bjs.1800621017

Cited by 36 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, noting the lack of specificity shown by Roberts and colleagues [29] it is perhaps not surprising that our prospective study did not confirm a significant correlation between changes in serum ORO and therapeutic response.…”

Section: Orosomucoidcontrasting

confidence: 53%

“…Roberts and colleagues reported that 18 out of 24 (62%) patients with metastatic disease had an elevated serum ORO value (>0.88 g/l) at diagnosis of systemic disease [29]. However, the lack of specificity of orosomucoid even in advanced breast cancer was shown by the fact that the mean serum ORO concentration of patients with Crohns disease was higher than the mean value of patients with disseminated breast cancer.…”

Section: Orosomucoidmentioning

confidence: 94%

See 1 more Smart Citation

Prospective assessment of the role of five tumour markers in breast cancer

Robertson

Pearson

Price

et al. 1991

Cancer Immunol Immunother

View full text Add to dashboard Cite

Retrospective analysis previously identified significant elevation of five tumour markers, carcinoembryonic antigen (CEA), ferritin, orosomucoid. C-reactive protein and erythrocyte sedimentation rate (ESR), in patients with systemic breast cancer and showed that changes in each of these markers individually correlated significantly with therapeutic response. In this study we have prospectively tested these findings. None of the five markers was significantly elevated in primary breast cancer compared to normal control or benign breast disease groups. They therefore appear to have no role either in screening or in the differential diagnosis of breast cancer. There was a significant elevation of all five markers in patients with systemic breast cancer (P less than 0.0001: analysis of variance) but sequential changes in CEA and ESR only correlated significantly with the UICC-assessed response. Prospective confirmation of the correlation between changes in serum CEA and ESR provides the basis for using these markers in the assessment of response to therapy in patients with systemic breast cancer.

show abstract

Section: Orosomucoidcontrasting

confidence: 53%

Section: Orosomucoidmentioning

confidence: 94%

Prospective assessment of the role of five tumour markers in breast cancer

Robertson

Pearson

Price

et al. 1991

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Further, the levels of these proteins have correlated closely with the spread of disease [12,19,21]. These findings have led us to raise the question as to how these glycoproteins might affect the responses of immunologically competent cells.…”

Section: Introductionmentioning

confidence: 96%

Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer

Samak

Edelstein

Israël

1982

Cancer Immunol Immunother

View full text Add to dashboard Cite

Acute-phase reactant proteins reach abnormally high levels in patients with cancer, and correlate with the extent of disease. In this study, several acute-phase glycoproteins, and serum albumin as a control, were tested at different concentrations for their ability to modify the blastogenic response of lymphocytes from 30 normal donors to PHA and the chemotactic response of monocytes from 15 normal donors to casein. In high concentrations approximating those found in cancer patients, but not in normal concentrations, haptoglobin and fibrinogen inhibited both functions to different degrees. Orosomucoid inhibited only monocyte chemotaxis, while ceruloplasmin and alpha 1-antitrypsin affected neither function. Increasing concentrations of PHA did not overcome the blocking effect of haptoglobin and fibrinogen on blastogenesis, suggesting that PHA-protein interaction was not responsible for the effect observed. The three proteins that did not suppress blastogenesis individually did so strongly when combined. It is suggested that these glycoproteins, synthesized by the liver in response to an inflammatory stimulus, may act as 'non-specific blocking factors' protecting tumors against the host's immunological attack. This non-specific blocking activity of the acute-phase proteins may contribute to the 'immune escape' of the tumor.

show abstract

“…However, changes in serum levels which tollow a distinct pattern as detected by serial measurements in a single patient might reflect tumour growth. This approach was recently advocated in the literature and promising results in some patients with colorectal cancer [13,14], breast cancer [15] and neuroblastoma [16] have been claimed. In the present investigation three APR (cq-acid glycoprotein, haptoglobin and C-reactive protein) and three CC (C4, C3-proactivator, and C9) have been determined in a longitudinal fashion in 20 patients with invasive cervical carcinoma.…”

Section: Introductionmentioning

confidence: 99%